Article

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myeloma

2026-08-07

Abstract excerpt

<h4>ABSTRACT</h4> Multiple myeloma (MM) is a plasma cell malignancy that frequently harbors activating mutations in NRAS and KRAS oncogenes. Previous clinical trials targeting the Ras/MAPK oncogenic pathway with MEK inhibitors (MEKi) were met with limited efficacy, and newer generation of Ras inhibitors (RASi) have not been specifically evaluated in MM patients. To investigate the vulnerabilities of Ras-mutant...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d6f7149e-5337-50e2-9073-dae6f0eeb890
DOI: 10.64898/2026.08.06.743109

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myelomaDOI 10.64898/2026.08.06.743109Read

Stability of c-Myc protein differentiates Ras oncogene addiction and MAPK pathway dependency in Ras-mutant multiple myelomaSemantic proximity Read

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activationSemantic proximity Read

Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.Semantic proximity Read

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.Semantic proximity Read

Pathway-Directed Therapy in Multiple MyelomaSemantic proximity Read

Integrated Phosphoproteomics and Transcriptional Classifiers Reveal Hidden RAS Signaling Dynamics in Multiple MyelomaSemantic proximity Read

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma.Semantic proximity Read

<em>KRAS/NRAS</em> Mutation-Associated Transcriptional Dysregulation Identifies <em>NRL</em>, <em>CREM </em>and <em>IL-6</em> as Candidate Prognostic Biomarkers in Multiple MyelomaSemantic proximity Read

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival.Semantic proximity Read

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.Semantic proximity Read

Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma.Semantic proximity Read

Ponatinib for RAS-Driven Multiple Myeloma: Efficacy in the High-Risk VQ Myeloma ModelSemantic proximity Read